Our mRNA and protein expression measurements(Figure 5 and 6) weretherefore designed based on IFN-α signaling and did not include an IL-24 group.Our goal was to understand if combining IFN-α with IL-24 could enhanceanti-tumor activity via inhibition of STAT3 to promote anti-angiogenic effects. The gene discussed is IFNA1; the disease is neoplasm.